Biotolerance of a semisolid hydrophobic biodegradable poly(ortho ester) for controlled drug delivery.
We evaluated the biotolerance of a new semisolid poly(ortho ester) (POE) intended for controlled drug delivery. Two different investigations were carried out in rats: subcutaneous injections and the cage-implant system. Sodium hyaluronate (SH), 1%, in phosphate buffer was used as a noninflammatory control. When injected subcutaneously in rats, the POE induced a mild and local inflammation at 3 and 7 days followed by a minimal chronic inflammation at 14 and 21 days. When using the cage-implant system, we quantified the inflammatory components of the exudate surrounding the implanted material within the cage system at 3, 7, 14, and 21 days. The total leukocyte and macrophage concentrations were higher only at 7 days for both SH and POE compared to the control (empty cage). The other parameters were not significantly different from the control. These results show that POE is well-tolerated by rats when used subcutaneously.
Bernatchez
S F
SF
School of Pharmacy, University of Geneva, Switzerland.
Merkli
A
A
Tabatabay
C
C
Gurny
R
R
Zhao
Q H
QH
Anderson
J M
JM
Heller
J
J
D000818:Animals; D001842:Bone and Bones / Q000378:metabolism*; D003692:Delayed-Action Preparations; D004343:Drug Implants; D006820:Hyaluronic Acid / Q000633:toxicity; D007249:Inflammation / Q000139:chemically induced / Q000473:pathology; D007279:Injections, Subcutaneous; D007958:Leukocyte Count / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects; D008422:Materials Testing; D011091:Polyesters / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014783:Viscosity
D003692:Delayed-Action Preparations; D004343:Drug Implants; D011091:Polyesters; D006820:Hyaluronic Acid